






Issue 2 March/April 2002
At midnight on Dec. 31, 2001, for the first time
in history, a currency that had not been debased
through inflation had its legal tender status re-
voked. From its introduction in 1948, the German
mark was one of the world’s strongest currencies
and was viewed as one of the great achievements
of the postwar Bonn Republic. Its replacement by
the euro signifies a major milestone in European
integration. On Jan. 27, the mark was joined by
the Dutch guilder, and on Feb. 9 the Irish punt dis-
appeared into history. The French franc became a
thing of the past on Feb. 17, and at midnight on
Feb. 28 all of the legacy currencies of the 12-nation
euro area ceased to be legal tender. The euro is now
the only legal tender in most of Western Europe.
The introduction of euro banknotes and coins,
which began on Jan. 1 of this year, was a great
success. The predictions of long lines at retail out-
lets and railway stations were not borne out, and the
European public has embraced the new currency
with an enthusiasm that surprised even its most
ardent supporters. There were glitches, but they
were few. The cash changeover, far from marking
the beginning of the end of economic and mone-
tary union (EMU) as some had expected, simply
marks the end of the beginning.
It’s as daunting a task today to divine how biotechnology will affect
future economic activity as it might have been for economists in the 18th,
19th and 20th centuries to forecast how the steam engine, electricity and the
microchip would influence and eventually transform the world economy.
With the assistance of mind-boggling inventions, humankind’s bucolic exis-
tence has morphed into a world that our agrarian ancestors would scarcely
recognize. Biotechnology may change our world as much.
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Even though the bioscience industry has been around for 25 years and
the gargantuan task of mapping the human genome is complete, it’s still not
clear to what extent life science technology will affect our economy. Some
observers have already labeled this the “Biological Century,” betting that
advances in the life sciences will yield changes more momentous than those
of electricity and computers. Such predictions may be overinflated, but bio-
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technology has the potential to greatly
affect the economy.
Two types of economic effects are
already appearing in the nascent indus-
try. By analogy, they resemble the direct
splash of a stone tossed into a still pond
and the indirect rippling that follows.
Direct impacts from biotechnology include
such obvious pluses as research and de-
velopment (R&D) spending, sophisticated
jobs and tax revenues. Biotech compa-
nies have already sprouted up in many
parts of the country (Chart 1). Less visible
are the indirect effects, which include
improvements in quality of life and living
standards stemming from faster labor pro-
ductivity growth, better health products
and services, and a cleaner environment.
Landmark discoveries and novel in-
ventions have marked biotechnology’s
early history. These advances, propelled
by public funding and market incentives,
have increased interest and sustained
research activity. The current market-
place is characterized by intense compe-
tition but also by cooperation among
public and private stakeholders. However
the industry and supporting science play
out, the advent of biotechnology could
profoundly affect our lives.
What Transforms 
Market Economies?
Historically, the combination of
groundbreaking discoveries and subse-
quent commercialization has preceded
periods of prolonged economic expan-
sion. For example, the Industrial Revo-
lution in Great Britain was launched by
a confluence of new technologies with
commercial potential, such as the steam
engine. Later, the internal combustion
engine and electric power revolutionized
America. More recently, William Shock-
ley’s transistor and Jack Kilby’s micro-
chip laid the foundation for the Informa-
tion Age. All these eras of discovery and
applied research were followed by strong
economic growth.
Benchmark discoveries and innova-
tions such as steam power, electricity and
the microchip always garner the most
attention. But it’s usually not until the
technology is harnessed and products are
mass produced that we see economic
consequences.
Similarly for biotechnology, comple-
tion of the human genome map—while
transcendent in scientific importance—
will remain of little use commercially
until the information can be used to
combat human disease. Scientists are
making significant headway, but as
recently as 2001, one report said the
genome sequencing has not yet “materi-
ally affect[ed] the speed of development
of any given product.”
2 All this is not to
understate the gains in biotechnology in
recent years but to point out that it will
take time before products are conceived
and economies materially affected.
The Splash (Direct Impact)
Karl Ereky, a Hungarian engineer, first
coined the word biotechnology in 1919.
At the time, the term referred to all lines
of work involved in creating products
from raw materials with the aid of living
organisms. Today, the Biotechnology In-
dustry Organization (BIO) defines bio-
technology as “the use of cellular and
molecular processes to solve problems
or make products.”
In May 2000, BIO commissioned Ernst
& Young to determine the aggregate im-
pact firms involved in biotechnology have
on the U.S. economy. The study looked
at information from firms whose primary
business operations fell under five Stan-
dard Industrial Classification codes. While
some components of biotech activity are
not included in this definition, the report
gives an idea of the direct impact bio-
science is having on the economy.
3
The study reveals impressive growth
for the industry. The life science industry
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Biotechnology Timelinemore than doubled revenue from $8 bil-
lion in 1993 to $20.2 billion in 1999. R&D
spending was $11 billion in 1999, not
counting monies spent by colleges, uni-
versities and nonprofits. Total tax collec-
tions reached nearly $10 billion. Federal
taxes accounted for $6.8 billion of the
total and state and local taxes for the
remainder.
Completion of the human genome
and promises of new medicines sent
biotech share prices skyward in 1999
and 2000. Since then, sparse profits and
the realization that investment returns to
biotechnology are going to take some
time have kept overall stock prices sub-
dued (Chart 2). Profitability in the four
largest biotech firms has instilled recent
confidence in the sector, but the majority
of firms have yet to show a profit.
Biotech activity should continue to
expand. Overall health care and prescrip-
tion drug expenditures have increased
steadily in recent years. For example,
health care expenditures as a percentage
of GDP have grown from 8.8 percent in
1980 to 13 percent in 2000. Prescription
drug expenditures have been climbing
steadily since 1994 (Chart 3). The aging
of baby boomers will only augment such
trends. Recognizing the growth potential
in the industry, 41 states, including Texas,
New Mexico and Louisiana, are currently
pursuing economic initiatives to foster
growth in their emerging biotechnology
sectors. (See the box titled “BioTexas.”)
The Ripples (Indirect Impact)
Still a relative newcomer to the econ-
omy, biotechnology is already having a
positive indirect influence on economic
activity. Ernst & Young estimates that
biotechnology has an employment mul-
tiplier of 2.9. In other words, each job
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Within the biotech sector and across all industries, the pace of venture
capital investment in Texas is dominated by national fluctuations related to
changing conditions in U.S. financial markets. Last year, venture capital invest-
ment in Texas fell sharply, in line with the national decline (Chart B1), much of
which paralleled the fall in the Nasdaq stock index.
3
Abstracting from these general movements, Texas’ share of U.S. biotech
venture investment has varied within a low range of 2 to 3 percent in recent
years, even though Texas’ share of overall venture capital investment has risen
to about 7 percent, roughly the state’s share of the U.S. population. This
disparity, depicted in Chart B2, reflects that venture capital investment in other
high-tech industries and in non-health care services in Texas has outstripped
growth elsewhere in the United States, while Texas’ venture investments in
health care and biotech have lagged the national pace.
4
These differences likely stem from factors affecting the state’s regional
comparative advantage across industries. Nevertheless, like the vast majority 
of states, Texas’ shares of U.S. venture capital investment across industries is
also held down by the disproportionately high concentration of venture invest-
ment in California (44 percent of the U.S. total in 2001:4) and, to a lesser
extent, in New England and New York.
Texas life science firms could flourish if three key challenges are surmounted.
First, strong local scientific and academic norms must permit the rapid transla-
tion of academic results into competitive enterprises. Second, researchers and
stakeholders need good access to capital. And third, favorable royalty schemes
between the researcher and universities must protect incentive structures for
scientists wishing to take their intelligence to market.
Notes
1 THBI 2001 Index, Texas Healthcare and Bioscience Institute, 2001.
2 State Government Initiatives in Biotechnology 2001, September 2001. Report prepared for the Biotech-
nology Industry Organization by the Technology Partnership Practice, Battelle Memorial Institute and
State Science and Technology Institute.
3 For details on venture capital, see, “The Venture Capital Revolution,” by Paul Gompers and Josh Lerner,
in The Journal of Economic Perspectives, vol. 15, Spring 2001, pp. 145–68, and “How Does the Stock
Market Affect the Economy?” by John V. Duca, in Federal Reserve Bank of Dallas Southwest Economy,
September/October 2001.
4 The charts use data from the PriceWaterhouseCoopers Money Tree/Venture One survey through 2001:3.
This survey, which was revamped in 2001:4, is now called the PriceWaterhouseCoopers/Venture Eco-
nomics/National Venture Capital Association MoneyTree Survey.
BioTexas
The Texas life science industry is still in a fledgling stage. In recent years,
the industry has garnered considerable interest among investors, politicians,
consultants and community developers but remained relatively small. The Texas
Healthcare and Bioscience Institute (THBI) reported that the Texas life science
industry employed 50,650 people in 1999, only 0.5 percent of statewide
employment. Life science jobs in the state have continued to grow, however,
increasing at an annualized rate of 1.4 percent between 1997 and 1999.
1
Dallas, Houston, Austin and San Antonio are the life science strongholds,
making up two-thirds of the total industry employment. Even though it is small,
the industry is already having a positive effect on local economies. Compensa-
tion for those working in the industry is relatively high; life science employees
earn an average of $48,623, considerably higher than the state average of
$34,936.
Growth in the life science industry is unequivocally tied to the rate of
intellectual property generation and commercialization. Life science intellectual
property in Texas is growing quickly but still lags the powerhouses of California,
New York, Massachusetts, New Jersey and Pennsylvania. THBI reports that life
science patents issued to Texas residents increased 54 percent from 1997 to
1999, reaching a record 577 in 1999. Novel intellectual property will continue to
increase as individuals are trained in the life sciences. State institutions of
higher learning awarded 17,894 life science degrees in 1997.
Grants, endowments and investments enable researchers to discover new
life science technologies and bring them to market. Texas ranked third nation-
wide in 1999 in university dollars earmarked for life science research and
development. In all, just over $1 billion was spent, an 18.1 percent increase
over 1995. Most of the funding went to Baylor College of Medicine, Texas A&M
University and University of Texas Southwestern Medical Center at Dallas.
2
Texas researchers are beginning to bring biotechnology-related ideas to
market. According to THBI, income from Texas intellectual property increased
from $4.2 million to $25.6 million between 1993 and 1999. Although still small,
it represents more than a 500 percent increase. Such returns reinforce the
incentive to produce biotech research that can be commercialized.
The state government is committing vast resources to the Texas biotech-
nology cause. The 2001 Legislature appropriated $800 million for science,
engineering, research and commercialization activities. Various research parks
that include facilities for life science companies will benefit from the Legisla-
ture’s commitment. These facilities include BioHouston, the Texas Research
Park in San Antonio, the Woodlands Research Forest and the Harrington
Regional Medical Center in Amarillo.
Chart B1
Texas Venture Capital Financing Moves 
with Overall U.S. Venture Investment
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’01 ’00 ’99 ’98 ’97 ’96created in biotech generates an addi-
tional 2.9 jobs, resulting from biotech
firms’ purchases and consumer spending
of biotech employees. With the multiplier
effect, biotech’s total impact on employ-
ment comes in at more than 437,000 jobs.
Ernst & Young gives biotech a 2.3
revenue multiplier, increasing the total
impact on revenues from biotechnology
to $46.5 billion. The personal income
multiplier is estimated to be 2, which re-
sults in a $28.8 billion total impact on
personal income from the industry.
Biotechnology’s contributions to medi-
cine and health care are growing rapidly,
promising to increase human longevity
and healthiness. To the extent that biotech-
nology results in new treatments for old
ailments, people will become more pro-
ductive over their lifetimes.
In addition, improved strains in agri-
cultural crops have helped increase yields
for many years. Research and develop-
ment of more-productive and disease-
resistant crops have enabled output per
farmer to increase steadily. Improvements
in quality of life will continue as scientists
further harness biological processes to
clean up hazardous waste and contami-
nated areas. Environmental remediation
is growing fast as a result of increased
public demand for a cleaner, safer and
more natural living space.
Structure of the Bioscience
Industry: Form Follows Function
The structure of the bioscience in-
dustry is in flux. Advances in biotech 
science have led to an evolution of the
industrial structure: from the domination
of large-scale firms to the entry of many
small, innovative start-ups to alliances
between the large and small for a more
efficient way of doing business.
Stanley Cohen and Herbert Boyer’s
transfer of DNA from one organism to
another in 1973 was a major milestone in
biotech, leading to an explosion of new
research and production mechanisms and
a change in the industry’s organization.
This advance in genetic science pro-
pelled the industry along two different
paths, according to Henderson, Orsenigo
and Pisano (1999).
One path employed genetic science
as a process technology, that is, using the
methods of Cohen and Boyer to mass
produce proteins as therapeutic agents.
Genetic engineering required competency
in the new techniques and a different
type of R&D effort by firms. Before
genetic engineering, a small number of
proteins could be manufactured either
from natural sources or by organic chem-
ical methods. Genetic engineering made
it possible to produce large quantities of
proteins, opening a completely new area
for drug research. Henderson, Orsenigo
and Pisano argue that this process tech-
nology was the force behind the first
large-scale entry into the biotech industry
since the early post-World War II period.
Zucker, Darby and Brewer (1998) also
note that the number of firms using
biotechnology “grew from nonexistent to
over 700 in less than two decades, trans-
forming the nature of the pharmaceutical
industry.”
The second path employed biotech-
nology techniques as a research tool for 
discovering and manufacturing conven-
tional, “small molecule” drugs.
4 This trend
reinforced the dominance of the large
pharmaceutical firms, which were able
to leverage their competency in chemical
R&D processes to build off the knowl-
edge already codified in the academic 
literature.
The academic research done in uni-
versities in the 1970s and 1980s spawned
many small, innovation-rich start-up com-
panies, beginning with Genentech, formed
by Boyer and Robert Swanson in 1976.
The 1990s brought much merger activity
as large biotech companies purchased
innovative start-ups.
5 Often, the mergers
occurred because the target R&D firms,
while rich in talent, were poor in capital
and resources to commercialize products.
These start-ups needed the distribution
and production processes of larger firms
to take their products to market. Con-
versely, larger firms needed new ideas
but often found it more economical to
acquire brain-rich start-ups than to ex-
pend scarce resources for cutting-edge
in-house research. Moreover, by buying
an established firm, a larger firm was
able to mitigate the uncertainty inherent
in R&D efforts.
Public and Private Collaboration
Much basic biotech research has been
publicly funded and conducted at uni-
versities because the research is a public
good and has positive spillovers. (See
the box titled “Biotech: A Public Good?”)
The National Institutes of Health (NIH)
funds the majority of biotech research in
the United States. The NIH budget in
2001 was $20.5 billion, or roughly twice
the size of private spending on biotech
R&D in 1999 (the most current year for
which we have data). About 82 percent
of the NIH budget is for grants and con-
tracts that support research and training
in universities. Another 10 percent goes
toward in-house research. Henderson,
Orsenigo and Pisano report that NIH
spending on basic research has had a
significant effect on the productivity of
the large firms that received funds.
Studies suggest that the public-good
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and click on “Events.”aspects of biotech research make it costly
to work through the market and that
mergers and acquisitions are one way of
internalizing these costs. Gaisford et al.
(2001) posit that restructuring activity
can be motivated by institutional failure
or weak patent protection and incomplete
contracts. Disputes between biotech com-
panies over the control of patent and
contractual rights to key technologies
have landed many of them in court. Ver-
tical integration solves some of these
contractual problems and helps firms
protect the returns on their innovations.
Mergers and acquisitions also allow
companies to take better advantage of
their relative strengths. Life science firms
generally have different comparative
advantages in producing knowledge,
whether it be codified (designs, formulas,
patents), tacit (learning-by-doing) or dis-
tributed (only valuable if used in con-
junction with others). Because transferring
knowledge between independent firms
through the market is difficult, firms ver-
tically integrate to make such transfers
more efficient.
6
In addition to corporate restructur-
ing has been the rise of strategic alliances
among firms. Such partnering allows two
or more firms to combine forces without
bearing the cost of merging or coordi-
nating a joint venture. Alliances have been
important for biotech innovation because
established firms find it difficult to keep
abreast of all the industry’s technological
advances, according to Filson and Morales
(2001). Their study shows that firms in 
a strategic alliance purchase some of
their R&D partner’s equity, thus gaining
shareholder influence to better monitor
the R&D firm and to allay some of the
investment’s uncertainty. Some recent
examples are collaborations between
Nanogen and Hitachi; Affymetrix and
Perlegen; OSI Pharmaceuticals, Genen-
tech and Roche; Bayer and CuraGen;
and Abbott Laboratories and Millennium
Pharmaceuticals.
7
Zucker, Darby and Armstrong (2001)
show that basic university science is inte-
gral to the successful commercialization
of scientific discoveries. Star scientists
provide the intellectual capital that de-
fines the firm’s core technology and
largely determines the company’s suc-
cess. The researchers also show that col-
laboration between academic and corpo-
rate scientists has a significant effect on
a wide range of firm performance meas-
ures. For example, for an average firm,
Zucker, Darby and Armstrong (1998) find
that five articles coauthored by academic
stars and the firm’s scientists imply about
five more products in development, 3.5
products on the market and 860 more
employees.
According to Zucker, Darby and
Brewer (1998), the location of top scien-
tists also predicts where new technology
firms will locate. The bioscience indus-
try’s growth and location from 1975 to
1990 was dependent on the growth and
location of intellectual capital. Intellec-
tual capital flourished around the great
universities (the authors cite 20), but the
existence of outstanding scientists played
a role over and above the presence of uni-
versities and government research fund-
ing. Local venture capital also was im-
portant to the industry’s growth.
The evolution of the bioscience in-
dustry provides insights into how states,
all now vying for a piece of the biotech
pie, can focus their efforts. The recipe
for success seems to start with strong
academic institutions and laboratories with
a good research base. These institutions
will provide the groundbreaking research
and draw top scientists to the region.
Another ingredient is an institutional struc-
ture that will aid technology transfer or
commercialization of innovations arising
from the research and that will foster
start-up companies. In the long run, firms
will go where the research and start-ups
are percolating.
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Biotech: A Public Good?
Public funding through government agencies and universities has been a major factor in the history
of biotech research. Such funding is an efficient way to advance biotech research, which, like all basic
research, has certain public-good characteristics and positive spillover effects.
Public goods are those in which consumption is nonrival and nonexcludable or where exclusion is
very costly. For example, the outcome of a biotech experiment can be considered a public good. When 
the experiment’s outcome is published, it becomes hard to exclude people from seeing the results
(nonexcludability). And, an individual knowing the results (consuming the good) does not compete with
another’s ability to consume (nonrival in consumption). In fact, the additional cost of another person
knowing the results is nil.
1
The nonexcludability characteristic also gives rise to what is called a free-rider problem. Consumers
of the good have no incentive to pay when they know they can get the good for free. Because of the non-
excludable nature of biotech “goods,” firms have no economic motivation to advance the research. For this
reason, most public goods (such as basic research, national defense and so forth) are paid through taxes. 
Moreover, if a good has positive spillover effects, benefits accrue to people other than those paying
for the good. Private production of the good then would be less than optimal because it would not take
account of the spillover benefits accruing to consumers who did not specifically buy and pay for the good.
Possibly recognizing the public-good qualities of basic biotech research, the Morrill Acts of 1862
and 1890 were passed in response to the growing demand for agricultural and technical education. The
beneficiaries of the Morrill Acts were institutions designated as land-grant universities, the first publicly
supported venues for biotech research. The acts provided these institutions with federal land grants and
monies. A key component of the system was the Agricultural Experiment Stations, which promoted
agricultural research.
The majority of public funds for biomedical research now flows through the National Institutes of
Health (NIH). NIH first emerged in 1887 as the Laboratory of Hygiene in Stapleton, N.Y. This one-room 
lab was initially set up to find cures for infectious diseases such as cholera, typhoid fever and smallpox. 
In 1930 the lab was expanded, reorganized and renamed the National Institute of Health. In 1948, the lab
widened its scope, and four institutes were created to support research on cardiovascular disease, mental
illness, infectious diseases, and experimental biology and medicine. These days, the goal of NIH is to
acquire new knowledge to help prevent, detect, diagnose and treat diseases and disability.
Because there is quite a bit of learning by doing in biotech research, Zucker, Darby and Armstrong
(2001) argue, some biotech innovations are excludable. The excludability arises from the complexity or
tacitness of the information necessary to practice the innovation. This information is held by a small
number of star scientists and hence does not disseminate as quickly. However, the authors do suggest
that publicly funded research greatly benefits the biotech industry. Public funding of biotech research can
be justified insofar as it continues to display public-good qualities. 
Note
1 This is in contrast to a private good, such as food, where one person’s consumption leaves less for others and it is relatively cheap 
to prevent others from consuming it.
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Conclusion
Life science as a formal industry has
only been around for a quarter century,
but using living organisms to advance
human life quality has transpired for
thousands of years. Public funding has
expedited growth in the life sciences and
catalyzed private interest in the sector.
Like the gains from trade among coun-
tries, trading among private and public
entities has been key to industry growth
in recent years. In particular, universities,
labs and incubators laden with ideas and
brainpower have collaborated with in-
dustry leaders whose deep pockets have
enabled them to produce, market and
sell new life science products. While it is
too early to tell what the overall impact
of biotech will be, the industry’s effect





Thompson is an associate economist, 
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Notes
1 The terms life science technology and biotechnology are used inter-
changeably in this article.
2 See Ernst & Young (2001), p. 5.
3 Standard Industrial Classification codes included in the definition are
2833, 2834, 2835, 2836 and 8731. See Ernst & Young (2000).
4 See Henderson, Orsenigo and Pisano (1999), p. 283.
5 For example, Monsanto bought Calgene and Agracetus, Dow Chemi-
cal acquired Mycogen and Dupont bought Pioneer Hi-Bred. More
recently, about 12 acquisitions took place from 2000 to mid-2001.
6 See Gaisford et al. (2001), p. 178.
7 See Ernst & Young (2001), p. 58.
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